Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 210-218

  Wiley, A ^a   Katsaros, D ^b   Fracchioli, S ^b   Yu, H ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

DNA methylation; IGFBP 3; Ovarian cancer; Prognosis

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOSOL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; EVALUATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOGENESIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN METHYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; STATISTICAL ANALYSIS; TISSUE LEVEL; TUMOR VOLUME;

BIOPSY, NEEDLE; CARCINOMA; COHORT STUDIES; DNA METHYLATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33645366728     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00299.x     Document Type: Article

References (38)

1. Ozols RF Schwartz PE Eifel PJ. Chapter 32.4: ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In DeVita VT Jr. Hellman S Rosenberg SA eds. Cancer: principles and practice of oncology. Philadelphia, PA Lippincott Williams and Wilkins 2001 1364 94.
2. Jemal A Murray T Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 10 30.
3. Arias E Anderson RN Kung H Murphy SL Kochanek KD. Deaths: final data for 2001. Natl Vital Stat Rep 2003 52 1 116.
4. McGuire PM Hoskins WJ Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334 1 6.
5. Conover CA Hartmann LC Bradley S et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res 1998 238 439 49.
6. Vella V Sciacca L Pandini G et al. The IGF system in thyroid cancer: new concepts. J Clin Pathol: Mol Pathol 2001 54 121 5.
7. Stoll BA. Association between breast and colorectal cancers. Br J Surg 1998 85 1468 72.
8. LeRoith D Roberts CT Jr.. The insulin-like growth factor system and cancer. Cancer Lett 2003 195 127 37.
9. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000 278 E967 76.
10. Butt A Firth SM Baxter RC. The IGF axis and programmed cell death. Immunol Cell Biol 1999 77 256 62.
11. Katsaros D Yu H Levesque MA et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 2001 37 478 85.
12. Firth SM Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002 23 824 54.
13. Yu H Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000 92 1472 89.
14. Rajah R Valentinis B Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997 272 12181 8.
15. Lukanova A Lundin E Toniolo P et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002 101 549 54.
16. Flyvbjerg A Mogensen O Mogensen B Nielsen OS. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997 82 2308 13.
17. Jones PA Laird PW. Cancer epigenetics comes of age. Nat Genet 1999 21 163 7.
18. Chang YS Wang L Liu D et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002 8 3669 75.
19. Hanafusa T Yumoto Y Nouso K et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002 176 149 58.
20. International Federation of Gynecology and Obstetrics. Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987 56 263 4.
21. Serov SF Soully RF Sobin LH. Histological typing of ovarian tumors. International Histological Classification of Tumors. Geneva, Switzerland World Health Organization 1973 37 42.
22. Karasik A Menczer J Pariente C Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994 78 271 6.
23. Zumkeller W. IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumor growth? J Clin Pathol: Mol Pathol 2001 54 285 8.
24. Giovannucci E IGFs, IGFBPs and risk of prostate and breast cancer. Horm Res 1991 51 Suppl. 3 34 41.
25. Giles ED Singh G. Role of insulin-like growth factor binding proteins (IGFBPs) in breast proliferation and metastasis. Clin Exp Metastasis 2003 20 481 7.
26. Oh JS Kucab JE Bushel PR et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002 4 204 17.
27. Martin JL Baxter RC. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-2 (IGFBP-3) in breast cancer cells. J Biol Chem 1999 274 16407 11.
28. Kim H Ingermann AR Tsubaki J Twigg SM Walker GE Youngman O. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004 64 2229 37.
29. Miyamoto S Yano K Sugimoto S et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 2004 64 665 71.
30. Lo YMD Wong IHN Zhang J Tein MSC Ng MHL Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 1999 59 2899 903.
31. Yegnasubramanian S Kowalski J Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004 64 1975 86.
32. Kim D Kim JS Ji Y et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and poor prognosis in primary non-small cell lung cancer. Cancer Res 2003 63 3743 6.
33. Komine C Watanabe T Katayama Y Yoshino A Yokoyama T Fukushima T. Promoter hypermethylation of the DNA repair gene o6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003 13 176 84.
34. Anzola M Cuevas N Lopez-Martinez M Saiz A Burgos JJ de Pancorbo MM. No association between GSTP1 aberrant promoter methylation and prognosis in surgically resected hepatocellular carcinoma patients from the Basque Country (Northern Spain). Liver Int 2003 23 249 54.
35. Bender CM Gonzalgo ML Gonzales FA Nguyen CT Robertson KD Jones PA. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 1999 19 6690 8.
36. Miki K Shimizu E Yano S Tani K Sone S. Demethylation by 5-aza-2′deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer lines. Oncol Res 2000 12 335 42.
37. Adis R&D Profile. Decitabine: 2′-deoxy-5-azacytidine, Aza dC, DAC, Dezocitidine, NSC 127716. Drugs R D 2003 4 352 8.
38. Issa JJ Garcia-Manero G Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza- 2′deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004 103 1635 40.